Join
Live feed
·
PRReleasevia Quantisnow
Medicenna Therapeutics Corp. logo

Medicenna to Present 4 Year Follow-up Phase 2b Bizaxofusp Survival Data in Recurrent Glioblastoma at the Society for Neuro-Oncology 2023 Annual Meeting

ByQuantisnow·Wall Street's wire, on your screen.
MDNA· Medicenna Therapeutics Corp.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track MDNA (Medicenna Therapeutics Corp.) and more on Quantisnow.